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PREFACE 
Seal Herpesvirus Type I (SeHV-I) causes a debilitating disease in young seals 
and sea lions in the wiId and in rehabilitation centers. Currently, there i s  only one 
diagnostic test available for detecting antibodies: the serumlvirus neutralization 
test (SNT), Specific objectives of this project were to 1 )  produce and 
characterize monoclonal antibodies to SeHV-I for use in developing a 
competitive ELISA to detect SeHV-1 antibody, 2) if objective 1 failed, develop an 
indirect enzyme Iinked irnrnunosorbant assay (I'ELISA) for detection of antibodies 
to SeWV-1. The results of this study will provide a quicker, more sensitive, and 
Eess expensive method for detection of antibodies to SeHV-I in marine mammal 
sera. 
ACKNOWLEDGEMENTS 
I would like to express my deepest gratitude to my major advisor, Dr. J. T. Saliki 
for his supervision, constructive guidance, strong support, and fiendship. I 
would also like to extend my gratitude to my committee members, Drs. R. Eberle 
and Jerry Malayer, for their additional guidance and support. I would also like to 
thank Dr. William Edwards and the staff of the Oklahoma Animal Disease 
Diagnostic Laboratory for their support and providing me with this research 
opportunity, equipment, and space. 
Additionally, I would like to express my appreciation to Dr. S. A. Ewing for his 
financial support, added guidance, and friendship. Also, I would like to express 
my appreciation to those who provided assistance during this study: Mrs. 
Shannon Castletine and Mrs. Emily Cooper. 
I would also like to send my appreciation to my family, who through their 
support, encouragement, and understanding helped make this process possible. 
Finally, 1 would like to thank the Veterinary Biomedical Sciences and College of 
Veterinary Medicine for their support over the past hw years. 
TABLE OF CONTENTS 
Chapter Page 
I. INTRODUCTION AND LITERATURE REVEW 
Introduction to Herpesviruses 
Introduction to Seal Herpesvirus Type I 
Seal Herpesviruses 
Geographical Distribution 
Seal Herpesvirus Type I Virology 
Sfmctural Properties 
Cell Cultures and Cytopathic Effect 
Clinical Aspects of Seal Herpesvirus Infections 
Pathology and Gross Path01 ogy 
Diagnostics 
Introduction to Diagnostics 
Virus Isolation 
SemmJVirus Neutralization 
Polymerase Chain Reaction 
Recent Advances in Seal Herpesvirus Study 
Conclusions 
II.  PRODUCTION AND CHARACTERIZATION OF 
MONOCLONAL ANTIBODIES FOR POSSIBLE USE 
JN A COMPETITIVE ENZYME LINKED 
IMMUNOSORBANT ASSAY 
2.1. Introduction 
2.2. Materials and Methods 
2.2.1 . Virus Isolate 
2.2.1.1. Plaque Purification and Expansion 
2.2.1.2. Polymerase Chain Reaction 
2.2.1.3. Virus Harvesting 
2.2.1.4. Virus Purification 
2.2.1.5. Final Antigen Preparation 
2.3. Monoclonal Antibody Production and 
Characterization 
2.3.1. Oklahoma State University Hybridoma Center 
2.3.2. Hybridorna Screening 
2.3.3. Monoclonal Antibody Characterization 
2.3.3.1 .Comparing MAb Binding to CrFK cells vs. 
SeHV- I Antigen 
2.3.3.2. Cross-Reactivity Between SeHV- 1 and SeHV-2 
2.3.3.3. Degree of Antigen Binding 
2.3.3.4. Test for a Competitive Monoclonal Antibody 
2.4. Results 
2.4.1. Production of monoclonal antibodies 
2.4.2. Characterization of monoclonal antibodies 
2.5. Discussion 
111. Development and Evaluation of a Protein A-based 
indirect ELISA for Detection of SeHV-I Ab 
3.1. Introduction 
2.2. Materials and Methods 
3.2.1. Viruses 
3.2.2. Standard iELISA Procedure 
3.2.3. Protein A and G binding 
3.2.4. Species Binding 
3.2.5. Dilution Buffer 
3.2.6. Protein A Dilutions 
3.2.7. Determination of Optimal Serum Dilution 
3.2.8. Substrate Incubation 
3.3. Evaluating the iELISA 
3.3.1. Serum Neutral ization of Archived Samples 
3.4. Results 
3.4.11 . SNT Results 
3.4.2. iELISA Results 
3.4.3. Comparison of iELlSA and SNT 
3.5. Discussion 
IV. SUMMARY AND CONCLUSIONS 
V. REFERENCES 
VI. VITA 
LIST OF TABLES 
Table 
3.1 Geographical distribution of sea1 and sea I ion 
serum samples 
3.2 Agseement between SNT and EEISA for 
detection of antibody in 425 serum samples. 
LIST OF FIGURES 
Figure 
2.1. Summary of Monoclonal Antibody 
Characterization 
3.1. Protein A vs. Protein G Binding Results 
3.2a. Protein A Species Binding Results 
3.2b. Protein G Species Binding Results 
3.3. Protein A Dilution Series 
3-4. Substrate Incubation Time Results 
Page 
LIST OF ABBREVIATIONS 
AMEM 
cELISA 
CrFK cells 
DMEM 
FBS 
iELISA 
MAb 
OD 
PBS 
PBST 
PBST+FBS 
SeHV- 1 
SeHV-2 
SNT 
TBSE 
Vero cells 
Alpha minimum essential medium 
Competitive enzyme linked immunosorbant assay 
Crandell feline kidney cells 
DuPbecco's modification of eagle's medium 
Fetal Bovine Serum 
Indirect enzyme linked immunosorbant assay 
MonocIonal Antibodies 
Optical Density 
Phosphate buffered saline 
Phosphate buffered saline + .05% tween 20 
PBST + 10% fetal bovine serum 
Seal herpesvirus type 1 
Seal herpesvirus type 2 
Sendvirus neutralization test 
Tris buffered saline EDTA 
Afsican green monkey kidney cells 
CHAPTER I 
INTRODUCTION LITERATURE REVIEW 
1 .lo Introduction to Herpesviruses. 
Hef-pesvimses get their name from the Latin word, I~erpes, to creep. The 
family Herpe,vviridue contains three major subfamilies: AEphaherpesvirinue, 
Belaherpesvirinae, and Garnmaherpesvirinae. A1 pha-herpesviruses typically 
grow rapidly, lyse infected cells, and establish latent infections primarily in 
sensory nerve ganglia. Beta-herpesviruses have a comparatively restricted host 
range, and infect secretory glands, lymphoreticular tissue, kidneys and other 
epithelial tissues. Their replicative cycle is slow, and cell lysis does not occur 
until several days after infection. Gamma-herpesviruses have a narrow host 
range, and typically replicate and become latent in lymphoid cells. Some of these 
viruses also cause cytocidal infections in epithelial and fibroblastic ce!ls. All 
Herpesviruses cause lifelong, persistent infections. This usually occurs in the 
form of latency. 
Latent infections are not unique to herpesviruses, but are a defining 
characteristic of this virus family. Latency is a different pathway from the Iytic 
cycle and does not result in any clinical symptoms. The latent state is 
characterized by both the lack of efficient expression of all viral genes transcribed 
during productive infection and the activation of a unique latent-phase 
transcriptional program. To return to the lytic cycle, a process called reactivation 
must be induced, and this replication shift also must be governed by 
transcriptional regulatory mechanisms (Flint et aE., 2000). Excretion of infectious 
virus may occur continuously or intermittently without disease, or episodes of 
recurrent clinical disease with concurrent excretion of virus may mcur throughout 
the life of the host (Fenner et al., 1993). 
f .2. Introduction to Seal Herpavirus Type I: 
1.2.1. Seal Herpesviruses. 
Seal herpesviruses were first described following an outbreak of a flu-like 
Yird disease in July and August of 1984 (Borst et al, 1986). The outbreak 
initially began in a seal rehabilitation center off the coast of The Netherlands. 
This outbreak affected 23 seals in this center, killing I I .  The viral agent was 
described as a new member of the alpha-herpesvirinae subfamily. Antigenically, 
this new seal herpesvirus is reIated to both canine herpesvirus (CHV) and feline 
viral rhinotracheitis virus (FVRV) (Harder et al., 1996). The v i m  was designated 
Phocid herpesvirus I (PhHV-1) or seal herpesvirus type 1 (SeHV-1) (Osterhaus 
et al, 1985). 
A second herpesvirus, Phocid herpesvirus type 2 (PhHV-2) or Seal 
herpesvirus type 2 (SeHV-2), was described in a study of California sea lion 
populations off the California coast (Kennedy-Stoskopf et al, 1986). At the time 
S e w - 2  was not recognized as a Gamma-herpesvirus, but was rather classified 
simply as a herpesvirus. SeHV-2 was originally described as a co-infection with a 
retrovirus in lung tissue and was not believed to be the primary cause af death in 
that smdy (Kennedy-Stoskopf et al, 1 986). Se W- 1 and SeHV-2 were separated 
into distinct viruses based on antigenic and genetic characteristics (Harder et al., 
1996). S e w - 2  was shown to be a member of the subfamily 
Gammherpesvirinae and is much less virulent than Sew-I.  Unlike Sew-I  
there is no evidence of SeHV-2 causing any clinical symptoms in pinnepeds 
CZarnke et al, 1997). However, a recent study did indicate a possible correlation 
between ~ e W - 2  and a metastatic carcinoma of California sea lions and SeHV-2 
(Lipscomb et al., 20003. 
A serological study was performed on pinnepeds off the coasts of Alaska 
and Russia to determine the prevalence of both Sew-I and S e w - 2  (Zarnke et 
al, 1997). Serum antibody prevalence for SeHV-1 ranged from 22% to 779'0, 
whereas SeHV-2 had a lower prevalence ranging from 1 1 % to 50% in various 
sub-populations. It is evident that both types of seat herpesvirus are present in 
pinniped populations. Although there have not been any other outbreaks as 
significant as the initial outbreak in 1984, SeHV-1 is still causing deaths in wild 
populations and both seal herpesviruses are still being isolated from wild 
populations (Dierauf and Gulland, 200 1 ). Also, there have been recurring disease 
outbreaks in a seal rehabilitation center in the Netherlands (Harder et al, 1997). 
1.2.2. Geographical Distribution. 
Seal herpesvirus isolates have been obtained from seals off the European 
coasts of The NetherIands (Borst et al, 1986) and Germany (Howat et al, 19891, 
as well as from seals and sea lions off the coast of California {Kenndy-Stoskopf 
et aI, 1986; Gulland et al, 1997). Both types of SeHV occur in pinnipeds off the 
Atlantic and Pacific coasts of the United States (Harder et al., 1996; King et al., 
1998). Alaskan, Russian and Antarctic seal populations have also been shown to 
have mtibodies against both SeHV-1 and S e w - 2  (Zarnke et al, 1997; Stenvets et 
a!, 1992). These studies have indicated the presence of Sew-1 in worldwide seal 
and sea lion populations. 
1.3. Seal Herpesvirus Type I Virology: 
13-1. Structural Properties. 
Like other alpha-herpesviruses, the seal herpesvirus virion i s  enveloped 
and is about 150 in diameter, although size can range from 120nrn to 200nm. The 
capsid is an icosahedron 100nrn in diameter, and is composed of 150 hexamers 
and 12 pentamers. The capsid is surrounded by a tegument which is enclosed by 
the lipoprotein envelope (Fenner, et al., 1993). Herpesvirus genome consists of a 
linear &DNA molecule. The typical al pha-herpesvirus genome size is 
approximately 1 50lcbp. 
1.32. Cell Cultures and Cytopathic Effect 
Sew-1 grows readily in Crandell Feline Kidney (CrFK) cells. 
Cytopathic effects (CPE) are caused by margination and breaking of 
chomosomes (Flint et al., 2000). Visually, SeHV-1 CFE consists of cell 
rounding with inclusion bodies and a clumping into grape-like clusters. Syncytia 
formation was not observed in this study. 
1.3.3. Clinical Aspects of Infection. 
Clinical signs of Sew-I disease in seals differ between European and 
Pacific harbor seals infected with PhHV-1 (Dierauf and Gulland, 2001). SeHV-I 
symptoms include elevated body temperature (up to 40°C), inflammation of the 
oral mucosa, nasal discharge, coughing, vomiting, diarrhea, anorexia and 
lethargy, and reddening of the conjunctiva are more common in European harbor 
seals (Visser et al., 1991; Horvat et al., 1989). Additionally, small lesions in the 
oral mucosa, emphysema, pneumonia, and fatal generalized P W -  I usual 1 y 
occurs only in neonates (Borst et al, 1986; Gulland el al., 1997: Harder et al., 
1997). The duration of clinical disease ranged fsom 1 to 6 days (Borst et al, 
1986). 
1.3.4. Pathology and Gross Pathology. 
Laboratory and necropsy studies on seals dying of SeHV-t infection 
typically revealed an enlarged liver (more so in Pacific Harbor seals) (Dierauf and 
Gulland, 2001), with alterations only observed in the parenchyma and consisting 
of dystrophic degeneration varying in severity up to massive cuagulation necrosis 
(Borst et aal, 1986). Additionally, the presence of typical herpetic intranuclear 
inclusion bodies in phagocytic cells within the botryomycotic lesions of a captive 
harp seal has been reported (Daoust et al., 1994). 
1.4. Diagnostics. 
1.4.1. Introduction to Diagnosis. 
There are several means by which diagnosis of various pathogenic agents 
can be made. Isolation of the causative agent, in this case a virus, is a direct 
means of detection that can be performed on tissue specimens that are believed to 
be infected. Antigen detection is another means of detecting viral proteins 
directly. These methods include immunofluorescence assays (IFA) and 
immunohistochernical (IHC) detection. Another direct detection method involves 
the viral nucleic acid. Polymerase chain reaction (PCR) or reverse transcription 
PCR (RT-PCR) are the most common methods of detecting DNA and RNA 
respectively. Finally, serologicaI diagnosis is used as an indirect means of 
diagnosis. Serum antibodies directed against the virus can be detected by a 
number of assays, such as serudvirus neutralization test (SNT) and enzyme 
linked irnmunosorbant assay (ELI SA). 
1.4.2. Virus Isolation. 
V i m  isolation i s  performed to propagate infectious virus present in 
clinical specimens such as tissues, secretions and excretions. Specimens 
suspected of containing virus are processed and inoculated onto a cell culture. If 
virus is present, it can generally be identified by the appearance of CPE. 
Characteristics of CPE, such as syncytia formation, clustering of cells, its 
temporal development of CPE, and the type of cells infected can all help in 
identifying specific virus. If this is not sufficient, PCR or IFA can be used to 
make or confirm a viral diagnosis. Additionally, electron microscopy may be 
utilized to obtain confirmatory diagnosis based on structure, size, and shape of 
virions. 
1.4.3. SerudVirus Neutralization. 
The serum neutralization test (SNT) is the current gold standard for 
serologrcal diagnosis of SeHV-I and SeHV-2. The SNT is run by using a serum 
sample that is believed to contain antibodies against a particular virus. This 
sample is placed in a 96-well plate along with a known quantity of the vims that is 
being tested for. Jf the serum sample contains antiviral antibodies, these 
antibodies will neutralize the infectious virus. Thus, there will be an absence of 
CPE in a positive sample. If the serum sample is negative for the given viral 
&body, then CPE would be present because there are no antibodies to neutralize 
the virus. 
SNT is a very reliable test in virology. It is based on a specific reaction 
between serum antibodies and the virus. This is important in that few false 
positives will occur. Due to its specificity, SNT is the gold standard for diagnosis 
of many viruses. The time required to run the SNT assay can range from a day 
for very fast growing viruses to >7 days for slower growing viruses. 
1.4.4. Polymerase Chain Reaction. 
The purpose of PCR is to detect the presence of, and distinguish between, 
SeHV- 1 and S e w - 2  DNA. PCR amplifies a specific nucleic acid sequence using 
a defined primer set or sets. The amplified product is resolved by gel 
electrophoresis and visualized by eth~dium bromide staining. PCR has been used 
to detect the presence of SeHV-1 by amplification of a 1.6 kbp product (Harder et 
al., 1996; King et al., 1998) while no praduct i s  amplified from SeHV-2 using the 
SeHV- 1 primers. 
1.5. R e n t  Advances in Seal Herpesvirus Rearch .  
One group of researchers in Europe has described the production of 
monoclonal antibodies (MAbs) against SeHV- I and SeHV-2 (Lebich et al., 19943. 
These M b s  have proven useful in classifying new SeHV isolates into types 1 
and 2 (Harder et al., 1996; Lebich et a]., 1994). Furthermore, at least one anti- 
SdV-2 MAb is able to discriminate between American and European SeHV-2 
isolates by the failure to bind the American isolate (Harder et al., 1996). 
Therefore, there is a need to produce MAbs against American isolates of SeHV-1 
for use in antigenic typing and diagnosis of SeHV infections in the United States. 
En 1998, Harder et al. described the major immunogenic proteins of seal 
herpesviruses and their relationships to proteins of canine and feline herpesviruses 
in development of n vaccine. Additionally, a research group from The 
Netherlands have described a candidate phocid herpesvirus vaccine that: protects 
against feline herpesvirus infections as  well (Martha et aI., 2002). 
1.6. Conclusions. 
SeHV-1 is a significant cause of disease in seal populations worldwide. 
Means of diagnosing seal herpesviruses are limited. Research has been performed 
to develop monoclona1 antibodies with some success. It is important to take the 
monoclonal antibody research to the next step in producing MAbs to North 
American isolates for antigenic typing and diagnosis of SeHV-1 It is also 
important to develop a quicker and less expensive diagnostic tool that is amenable 
to testing large numbers of samples. Although the SNT is the current gold 
standard, it i s  more time consuming and labor intensive to perfom than an 
ELISA. Similarly, though it is highly specific, SNT is net as sensitive as an 
ELISA would be. This is important when dealing with low titer sera, or sera that 
are toxic to cell cultures. Additionally, since SeHV isolates from geographically 
distinct seal populations may vary in the antigenic properties, it is important to 
have a single test that can detect antibodies to all SeHV-1 isolates. 
CHAPTER IT 
PRODUCTION AND CHARACTEREATION OF MONOCLONAL 
ANTIBODlES TO SEAL HERPESVIRUS TYPE 1 
2.1. Introduction. 
Serum contains many different types of antibodies that are specific for 
many different antigens. Seldom are more than one tenth of the circulating 
antibodies specific for one antigen. This causes a variety of problems for 
diagnostic purposes using imrnunochemical techniques (Harlow and Lane, 1988). 
The fitst isolation of a homogeneous population of antibodies came from studies 
of B-cell tumors. Clonal populations of these cells can be propagated as tumors 
in animals or grown in tissue culture. A problem that developed was that in vivo, 
antibodies are synthesized primarily by plasma cells (Harlow and Lane, 1988). 
These plasma cells cannot be grown in vitrr) as a source of antibodies. However, 
Kohler and Milstein in 1975 developed a technique that allows the growth of 
clonal populations of cells secreting antibodies with a defined specificity. In this 
technique an antibody-secreting cell isolated from an immunized animal is fused 
with a myeloma cell, a trpe of B cell hunor. These hybrid cells or hybridomas 
can be maintained in vltro and can continue to secrete antibodies with a defined 
specificity (Harlow and Lane, 1988). 
Due to their exquisite specificity, monoclonal antibodies have become an 
invaluable ~ Q O F  in the diagnosis of several viruses. The speed, accuracy, and cost 
efficiency of tests using monoclonal antibodies have placed them in a primary 
role in the diagnostic field. Since they react with solid-phase antigen, the tests 
can be sun in a single day due to eliminating the need for virus growth in a cell 
culture as required by SNT. 
The advantage of n MAb-based ELISA is that a single conjugate (labeled 
anti-mouse IgG) can be used to detect anti-viral antibody in sera from a variety of 
species. This is important in that, a single protocol can be used to test many 
different species on a single plate, saving time and money. 
2.2. Materials and Methods. 
2-2.1. Virus Isolate. 
The SeHV- 1 isolate used in this study, designated as A92 1 0/4, was one of 
eight SeHV-1 isolates obtained from New York harbor seals in 1992-1 993 (JT 
Saliki, unpublished). SeHV-1 virions were purified from a single plaque via 
plaque purification. This procedure was performed to ensure genetic 
homogeneity of virus. PCR was used to confirm the identity of virus forming 
i~~dividual plaques as SeHV-I. Virus propagation and antigen preparation were 
prfomed once plaque purified virus had been expanded into working stocks. 
2.2.1.1. Plaque Purification and Expansion. 
A single 6-well tissue culture plate was used for virus plaque purification. 
Crandcll Feline Kidney (CrFK) cells were added at a concentration of 1 7 X 1 o4 
cetldwell diluted in Dulbecco's modification of Eagle medium (DMEM) 
(Mediatech hc, Hemdon, VA). Fresh DMEM ( 5  ml) was then added to each well 
of the 6-well plate. Cells were allowed to incubate for 3 days at 37OC with 5% 
COz to form a monolayer covering at least 90% of the well. Media was then 
removed from each well, and 100pl of 1 0-fold serial dilutions of virus [lo-' 
through in Alpha modification of Eagle minimum essential medium 
supplemented with Earle's salts, L-glutamine and antibiotics (100 U of penicillin 
and 100 p1 of streptomycin pet ml), (AMEM) (Mediatech Inc, Herndon, VA) 
without FBS were added to each well. The plate was incubated at 37°C for 30 
minutes while being gently rocked every 10 minutes. Approximately 5 mls of 
AMEM containing 2% methylcellulose was added to each well. The plate was 
then incubated for 4 days at 37OC with 5% GO1. Each day, the plate was 
observed for cytopathic effect (CPE). 
After four days of growth, individual plaques were visible. The 10 '~  virus 
dilution produced CPE in 80% of the monolayer, which was too much for single 
plaques to be picked. Twenty-four plaques were picked from the 1 o - ~  (7 plaques), 
1 o4 ( 15 plaques), and 1 0-' (2 plaques) virus dilutions by slowly pi petting 1 25pl of 
the plaque and surrounding area with a gentle scraping motion to obtain a small 
sample of surrounding cells. Each of these plaques were placed directly in 
individual wells of a 24-well plate with CrFK ceIls (2 X 1 cells/well in DMEM) 
in suspension. Plates were incubated at 37°C for 4-5 days to allow CPE in 75% 
of the monoIayer before the virus were harvested. 
The five fastest growing viral isolates were then inoculated onto CrFK 
cells in a T25 flask fbr injtial expansion. Each flask was  allowed up to 4 days to 
POW to at least 80% CPE before being frozen at -70°C overnight. The flasks were 
then thawed, the cells scraped, and the contents transferred into separate 15 ml 
tubes. The tubes were centrifuged at 900 X g for 15 minutes to pellet cell debris 
and the supernatant fluid aliquoted into snap cap tubes in 1 ml aliquots and frozen 
at -70°C until further use, The cell pellet was tested by PCR to insure that SeHV- 
1 was indeed the virus producing CPE. The one purified SeHV-I isolate showing 
the fastest and most uniform growth (identified as A92 T 014 ppB4) was used for 
continued expansion. This virus (150p1) was inoculated into a T75 flask 
containing a monolayer of CrFK cells and incubated at 37°C for four days. This 
T75 flask was fmzen at -7Q°C overnight, and virus supernatant harvested as 
described above. This expansion produced enough virus stock to infect a 
minimum of 30 T I50 flasks, while keeping the virus passage the same throughout 
the final expansion step. Finally, 33 TI 50 flasks, containing 2 X 106 CtFK cells 
in suspension were infected with 300yl each of the Sew-1  stock. Cultures were 
incubated for four days to allow virus CPE to involve at least 75% of the cell 
monolayer, and then fiozen at -70°C until further use. 
2.2.1.2. Polymerase Chain Reaction 
Polymerase chain reaction (PCR) was performed basically as described by 
Harder et a1 (1 996) with some modifications to the sequences being mplified. 
Published PCR primers for the SeHV-I glycoprotein B gene (Harder et a1, 1996) 
were ued to amplify a 16 16 bp product for SeHV-1. 
The two primers used were: 
@-I: S'aca act gta tgg tct gg-3' and 
gB-4: 5'-ggt aga aat tca cga tc(c/t) tc-3' 
The following PCR components were mixed into a thin-walled PCR tube 
(Fisherbrand): 5 .0~1  of iOX buffer, 2.0~1 MgClz (25mM stock concentration), 
2 .0~1  tach gB-1 and @-4 primer (15pM each), 1 .OpI dNTP (1 OmM of each), 
0 . 5 ~ 1  Taq polymerase (2.5 U), and 32.5~1 RNAse-free water. Contents were 
mixed well by vortexing and 5 . 0 ~ 1  of DNA solution was added. DNA isolation 
was perfomed as developed by Molecular Research Center, Inc (website, 
http://www.mrcgene. comldna. htm). 
Using a PTC-100 Programmable Thermal Controller from MJ Research 
Inc, themocycle conditions were set. These conditions were: one cycle of 94°C 
for 3 minutes, then 35 cycles o f  94°C for 30 seconds, 45°C for 1 minute, and 
72°C for 1 minute, followed by one cycle of 72°C for 10 minutes, and finaFIy 4°C 
to hold the contents indefinitely. After PCR was complete, contents were run 
along with a fragment size marker en a 2% agarose gel for 15 minutes then 
observed over W light for bands. 
2.2.1.3. Virus Harvesting. 
A11 33 SeHV-1 infected TI 50 flasks were thawed to room temperature. 
Cells were scraped into the medium, transferred to 50ml tubes, and centrifuged at 
900 X g for 15 minutes. The supernatant was poured off leaving the pellet with 
5mls of supernatant in each tube. Each pellet was sonicated for 2 minutes or until 
the w a s  completely dissolved using an 80% duty cycle with 70 input serting 
on a Branson Sonifier 450. The remainder of the supernatant was added back to 
each 50ml tube for re-centrifugation at 900 X g for 15 minutes. Supematants 
were then transferred into a new TI50 flask, and all the cell pellets were then 
discarded. The pooled supematant was then placed in polyallomer dm- 
centrifuge tubes and centnfuged at 150,000 X g for one hour in an ultra- 
centrifuge. Supematamt was then poured off and discarded and the virus pellet 
dried by inverting and gently tapping the tubes on a paper towel. Pellets were 
then re-suspended in 800 PI of steriIe PBS, combined into a singIe ultra-centrifuge 
tube, and stored at 4OC overnight. 
2.2.1.4. Virus Purification. 
Two sucrose solutions, 20% and 60%, were used to form a gradient for 
final purification of SeHV-I (Lebich et al., 1994). In clear ultracentrifuge tubes, 
20 ml of 20% sucrose was pipetted to fill each tube half way. Seventeen mls of 
40% sucrose was pipetted slowly using a glass pasteur pipette, below the 20% 
sucrose. Approximately 1-2 rnl of the virus solution was then added slowly on 
top of the 20% sucrose to avoid mixing. Tubes were centnfuged at 150,000 X g 
for 1 hour at 4OC. 
The virus particle layer remained between the 20% and 60% sucrose 
layers while cell fragments and organelles remained either on top of the 20% or 
below the 60%. The virus layer was removed using a pasteur pipette. The tip of 
the pipette was inserted along the side of the tube and slowIy removed the virus 
band to prevent mixing. Contents were then placed in a new ultracentrifuge tube, 
and sealed with parafilm to store overnight at 4°C. 
2.2.1.5. Final Antigen Preparation. 
Utracentrifuge tubes with sucrose gradient purified virus were filled with 
sterile PBS and centrifuged at 150,000 X g for 1 hour at 4°C. The supernatant 
was poured off, and tubes were dried by gently tapping on a paper towel. This 
process was repeated 2 times for each sample to assure removal of all sucrose. 
me pellet was then re-suspended in 6 n l s  of sterile PBS and transferred to a 50 
rnl tube. Contents were then sonicated at 80% duty cycIe and 80 input setting for 
5 minutes to insure complete dispersion of viral particles. The antigen was stored 
in 55 p1 aliquots at -70°C until needed. 
SeHV-2 antigen was prepared using the same method as SeMV-I, 
except SeHV-2 was grown on African green monkey kidney (Vero) cells. CrFK 
cell antigen was prepared by growing cells in T150 flasks. The flasks were 
scraped then transferred to 50 mI tubes and centrifuged at 900 X g for 10 
minutes. The supernatant (DMEM) was poured off, the pellets were re-suspended 
in 5 rnl of sterile PBS and sonicated as described previously. Both SeHV-2 
antigen and CrFK antigen were stored at -70°C until needed. 
2.3. Monoclonal Antibody Production and Characterization: 
2.3.1, Oklahoma State University Hybridoma Center. 
All MAb production was performed at the Oklahoma State University 
Hybridoma Center. Four mice were immunized three times at lbday intervals. 
After the final immunization, sera were tested using an indirect enzyme-linked 
immunosorbant assay CiELISA) against S e w -  I .  The mouse showing the highest 
level of antibody production was selected for monoclonal antibody pmduction. 
The initial step in MAb production was the fusion of spleen cells from immunized 
mice with a myeloma cell line to produce antibody-secreting hybridoma cell lines. 
The supernatant fluids from these hybridomas were tested for specific anti-SeHV 
antibody by ELISA technique. Positive hybridomas were expanded and stored in 
liquid nitrogen. 
2.3.2. Hybridoma Screening. 
Hybridorna screening was performed using an indirect ELllSA ( iELISA j. 
Imrnulon-2HB 96 well flat bottom plates (DYNEX, Alexandria, VA) were coated 
with 100 yl of SeHV-I antigen and CrFK antigen in alternating columns, each 
diluted 1:200 in carbonate buffer, 0.05 M, pH 9.6. All plates were stored 
overnight at 4OC. Plates were washed four times in PBST with 40 second soak 
times. PBST was not removed following the fourth soak. Plates were taken to 
the Oklahoma State University Hybridoma Center where the PBST was removed 
and replaced with 100 pIlwell of hybridoma supernatant. Plates were then 
returned to our laboratory for completion of the ELISA. Each plate was incubated 
at 37°C for one hour. Plates were washed four times in PBST with 40 second 
soak times, then dried by inverting each plate and gently tapping on a paper towel. 
Peroxidase conjugated anti-mouse (100p1) I@ (whole molecule) (Sima 
Chemical Co., St. Louis, MO), diluted 1:1000 in PBST was added to each well. 
Plates where then incubated for one hour at 37°C. Plates were washed and dried, 
and 95pl of substrate ( Img 3,3',5,5' tetramethylbemidine (TMB) plus 3 3 ~ 1  3% 
H202 per 10 ml of substrate buffer) was added to each well and allowed to 
incubate 4 minutes at room temperature en a plate rotator. The substrate reaction 
was stoppd by adding 2Sp1 of 2M H2SOa. Plates were read using a Molecular 
Devices E-max plate reader at 450 nrn wavelength. The positive cutoff was  
determined to be an optical density (OD) of 0.400 to eliminate low reacting 
samples. 
2 - 3 3  Monoclonal Anti body Characterization. 
Characterization of monoclonal antibodies was performed in a two tier 
format. First, M b s  were characterized as CrFK specific, or SeHV-I specific. 
Then, all the SeHV-1 specific binding MAbs were separated into SeHV-1 binding 
only, or S e w - I  and S e w - 2  cross-reactive. Monoclonal antibodies with low 
binding (less than .400 OD value) were still considered in this characterization, 
but were not further tested for diagnostic purposes. 
2.3.3.1. Comparing MAb Binding to CrFK cells vs. SeHV-I Antigen. 
Once the hybridomas were developed, it was important to test MAb 
supernatant for final characterization. T h i s  ELISA was performed as in section 
2.3.2. 
2.3.3.2. Cross-Reactivity Between SeHV-S and SeHV-2. 
Irnmulon-2HB 96-well flat bottom plates (DYNEX, Alexandria, VA) were 
setup in a similar manner zts described in 2.3.2, except that SeHV-1 Ag and 
SeHV-2 Ag, each diluted 1:200 in carbonate buffer, were coated in alternating 
columns, then stored at 4OC overnight, MAbs were then placed into three 
categories: SeHV- I p s i  tive1SeHV-2 negative, SeHV- 1 negativeiSeHV-2 
positive, or cross-reactive. 
2.3.3.3. Degree of  Antigen Binding. 
Each candidate MAb was re-tested to determine the optima1 dilution for 
use in a cELISA. All MAbs wete tested as described in 2.3.2., except that wells 
were coated only with SeHV- 1 Ag. MAbs with low 00 value (<0.400) were not 
considered as potential cELlSA candidate. 
2.3.3.4. Test for a Competitive Monoclonal Anti body. 
Irnmulon-2HB 96-well flat bottom plates (DYNEX, Alexandria, VA) were 
coated with SeHV-I antigen diluted 1 :200 in carbonate buffer, and incubated 
overnight at 4OC. Each plate was then washed 4 times in PBST and dried. SeHV- 
I positive seal serum samples having titers of 32, 64, and 96 and a negative 
serum sample (44) were diluted in triplicate 1.4, 1.8, 1:16, 1:32, 154, 1:128, and 
1 :256 then added (50yl) to individual antigen-coated wells. These serum samples 
were chosen because of their neutralizing titers via serum neutralization test 
(SNT). PBST was added to the final row as a negative control. Plates were 
incubated for 30 minutes at 37"C, and 5Oyl of each candidate MAb diluted 1 :lo, 
1 :50, and 1:250 was then added to each respective well without washing the 
plates. Plates were incubated for an additional 30 minutes, then washed and dried 
as described before. Antf-mouse IgG conjugate (100 p!) was added to each well 
and incubated for 1 hour at 37OC. Each plate was washed and dried as previously 
described, substrate was added (95~1)  to each plate, incubated for 5 minutes, 
reactions were stopped by adding 2 5 ~ 1  of 2M I-12S04, and the plates wete 
immediately read. Competition was determined by a decrease in OD in the 
sample wells from the MAb only well. 
2.4. Results: 
Plaque purification produced 6 isolates that grew as fast (5-6 days) or 
faster (4 days) and higher conformation than the non purified virus stock. All 6 
plaque purified ( designated as pp.) samples were determined to be SeHV-I via 
PCR. Isolate A92 1014 ppB4 was determined to be the isolate to be expanded due 
to having the highest consistency in speed and conformation of growth. The A92 
10/4 ppB4 was also tested by PCR and found to be SeHV-1 positive after final 
virus expansion. SeHV-T antigen was found to be concentrated at 6.65 mghnl, 
with a working coated concentration of ,03325 mgrnl. Sew-2 was found to be 
concentrated at 2.33 rnglml, and CrFK was found to have a concentration of 6.27 
mg/ml. 
2.4.1. Production of monoclonal snti'bodies. 
Nearly 100% of the initial hybrjdoma samples (109 out of 114) from the 
Oklahoma State Hybridoma Center reacted positively by iELISA during the 
screening phase. After fusion, 102 out of TO9 (93.6%) hybridomas that grew out 
retained SeHV-I positive reactivity in the iELISA {ranging from an OD of 0.294 
to 1.91 8). The 102 positive MAbs (>0.400) were selected for continuation of 
characterization. 
2.4.2. Characterization of monoclonal anti bodies. 
Ninety-five out of the 102 hybridomas were classified as seal herpesvirus- 
it positive, CrFK negative. Seven of the 102 hybridomas were classified as 
S e w - 1  negative, CrFK positive. These seven hybridomas were eIiminated from 
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Figure 2.1 Summary of Monodona! Antibody Characterization 
This fipure summarizes the monoclonal antibody characterization. Note that all MAbs 
that were CrFK specific were excluded from Further study. 
It was also fortunate that some were cross-reactive with SeHV- 1 and SeHV-2. 
As illustrated, there were no competitive MAbs. 
further study. Of the remaining 95 hybridomas, five were classified as SeHV-1 
positive, SeHV-2 positive. Ninety hybridomas were classified as SeHV- 1 
positive, SeHV-2 negative. F~nal classification of competitive MAb T 00% of the 
not comptitive (minimal change in OD value from MAb contml and sample 
wells). Results are summarized in figure 2.1. 
2.5. Discussion. 
In general, particulate antigens make excellent immunogens, because they 
are readily phagocytized (Harlow and Lane, 1988) as performed in our study. 
Our study successfuITy produced monoclonal antibodies against the New York 
SeHV-1 isolate, A92 1014 ppB4. High degree of success may be due to quaiity of 
antigen. Indeed, a high percentage (93%) of the MAbs in this study were specific 
for SeHV-I with only a few binding only to cellular antigen. This high 
percentage of SeHV-1 specific MAbs may be due in part to the plaque 
purification (producing virions from a single progeny which lowers the protein 
variability) and gadient purification (eliminating cell proteins) of virus used for 
immunization. This would have eliminated most of the CrFK antigens which 
would normally be present in infected cell or unpurified virus preparation. Of the 
95 S e w - I  positive Wbs, 5 were found to be cross-reactive with SeHV-2. This 
is unvsuaI in that SeHV-1 i s  an alpha-herpesvirus, whereas SeHV-2 is a gamma- 
herpesvirus. This could be explained in that these cross-reactive MAbs ate 
binding to some highly conserved proteins which are common m all subfamilies 
of herpesviruses (like capsid proteins or enzynes). These MAbs need to be tested 
n Western blomng or immunopmcipitation to determine what proteins are 
being recognized, especially with the 5 cross-reactive MAbs. The Western 
blotting will only be useful if these MAbs recognize sequential amino acid 
sequences due to the denaturing of protein bands. This testing is important in 
determining if these MAbs will cross-react with known shared antigenic proteins 
of feline and canine herpesvirus using an ELISA described by Harder et al. 
(1998). Additionally, it will be important to test each MAb to determine if any 
are neutralizing. 
This study failed to identify any competitive monocfonal antibodies. The 
reasons for this are unknown at this time. One possible expIanation i s  that the 
MAbs do not have enough affinity towards the vim! proteins. This may be solved 
by using poEyclonaI antibodies which use multiple epitopes. A second and more 
likely possibility i s  that the mouse recognizes SeHV-1 antigen by different amino 
acid sequences than seals do. This would allow for both seal sera and mouse 
MAbs to bind without blocking the other out, thus disallowing competitive 
interaction and preventing detection of serum antibodies by this assay system. 
Another possibility involves steric hindrance or blockage of epitope to which the 
sera binds. In this, MAb IgG binds to a dominant epitope surrounding the 
epitope(s) to which the serum Ig binds, thus preventing competition. Another 
possible, though unlikely suggestion is that the monoclonal antibodies were 
specific to epitopes that are specific to the New York harbor seal isolates and are 
not present in other regional isolates of 5eHV-1. OD values were similar when 
New York harbor seals with other seal and sea lion species from other 
geographical locations. It is uncertain if making more monoclonal antibodies than 
were produced in this study would have yielded different results. One study was 
able to produce rnonocEonal antibodies against European as well as American 
isolates, including some M b s  that could distinguish between the European and 
the American isolates (Lebich et al., 1994). Incf uding multiple SeHV- 1 isolates 
may be a solution to the problem in our study. 
Monoclonal antibodies produced in this study may still be useful in 
detecting protein bands via western blot. Western blot testing was beyond the 
scope of this study, however, it does need to be utilized in future studies of  this 
SeHV-1 isolate. 
DEWLOPMENT AND EVALUATION OF A PROTEIN A-BASED 
N3IRECT ENZYME LRlKED IMMUNOSORBANT ASSAY FOR 
DETECTION OF SeHV-I ANTWODIES 
3.1. Introduction. 
Indirect ELISAs (iELISA) are useful in detecting a wide variety of 
pathogens. The basic premise behind the iELISA is to have a plate with antigen, 
add the test serum, and have some method to detect the presence of s e m  
antibodies that bind to the antigen. Detection of serum antibodies requires some 
kind of a conjugate, one part of which recognizes the serurn antibodies and the 
other part providing the means of detection. The latter part usually takes the form 
of an enzyme such as a peroxidase or phosphatase. The conjugated enzyme 
catalyzes a color reaction that can be quantified based on an optical density (OD). 
The relative OD value obtained on control vs, viral antigen are then used to 
determine the positive or negative status of serum to a viral specific antigen. The 
advantage of the iELlSA over most other tests is that it can be used on virtually 
any pathogen. 
Although horseradish peroxidase-labeled anti-seal conjugate i s  
commercially available, it is cost prohibitive for routine diagnostic purposes 
because it has to be produced on order. To circumvent this obstacle, peroxidase- 
labeled Protein A and Protein G were tested as potential conjugates for detection 
of anti-SeHV-1 antibodies. Each of these proteins bind specificallv to the Fc 
region of IgG antibodies, but the species specificity of Proteins A and G are 
broader than that of anti-IgG antibodies (Harlow and Lane, 1988). This allows 
detection of serum antibodies of a number of different species that can be tested 
using a single conjugate. In developing an ELISA it i s  vital to maintain a high 
level of sensitivity (few false negatives) while allowing for a high degree of 
specificity (few false positives). 
3.2. Materials and Methods. 
3.2.1. Viruses 
Eight SeHV-1 isolates were obtained fm stranded harbor seals off the 
New York coast (J. T. SaEiki, unpublished). Virus stocks from isolate A92 1014 
ppB4 were grown using CrFK cells. One SeHV-I isolate was designated for 
propagation (A92 10/4) then cultured in a 2% methyl-cellulose Alpha MEM 
media with 2% FBS for plaque purification. Twenty four plaques were then 
obtained and placed in a 24-well flat bottom tissue culture pIate with CrFK cells 
at a concentration of 250,000 cells/well in 2 mls Dulbecco's Modification of 
Eagle Medium (DMEM) containing 1 0% FBS. Virus was then allowed 4 days to 
replicate to greater than 70% CPE. Six isolated plaques were transferred from the 
24 well plate to a T25 flask with 5mls fresh medium and CrFK cells. These 
plaques were chosen on the basis of degree of CPE and speed of growth. Each 
T75 Flask was allowed 4 days to attain 80% or greater CPE, then frozen at -70°C 
Each flask was thawed at room temperature, cells were scraped and 
@aced in individual 15mI tubes and centrifuged a? 1,000 X g for 15 minutes. 
Supernabnts were poured off into tubes, leaving 5 ml of supernatant on the cell 
pellet. The pellet was sonicated for 2 minutes to release virions from cells, after 
which the supernatant was placed back into the 15 ml tubes for re-centrifugation. 
the final supernatant, containing viable SeHV-1 virions, was stored in 4 ml 
aliquots at -70°C. 
3.2.2. Standard iELISA Procedure. 
A standard iELlSA procedure was used in various optimization 
experiments. In an Immulon-2HB 96 well flat bottom plate (DYNEX, 
Alexandria, VA), 1 00 p1 of purified SeHV-1 antigen diluted 1 :200 in carbonate 
buffer (0.05 M, pH 9.6) was added to each well and incubated at 4OC overnight. 
The plate was washed 4 times in PBS + .05% tween 20 (PBST) with 40 second 
soak times and dried by inverting the plate and gently tapping on a paper towel. 
Sample sera ( I  00 pF), diluted in PBST, was added to each well, then incubated for 
I hs at 37°C. Tho plate was washed and dried as previously described, 100 p1 of 
conjugate added to each well, and incubated as before. The plate was washed and 
dried as described before, 95 PI of substrate was added (containing 1 mg of 
3,3',5,5' tetramethylbemidine (TMB) and 3 3 ~ 6  per lOrnls of substrate buffer), 
then the plate was incubated at room temperature for 5 minutes. The substrate 
reaction was stopped by the addition of 2 5 ~ 1  of 2M HzS04, then immediately read 
for OD value using a Molecular Devices E-Max plate reader at a 450nm 
wavelength. 
3.2.3. Protein A and G binding. 
Protein A, isolated from the cell wall of S~aph~vlococcus atrrew, and 
Protein G, isolated from the cell wall of hemolytic Sfreptococcus strains C and G, 
were tested for conjugate purposes for an indirect ELISA. Proteins A and G bind 
specifically to the sscond and third constant regions Fc region of 1 6  antibodies 
(Harlow and Lane, 19881, which makes them ideal candidates for developing an 
ELlSA for marine mammals and other exotic species that peroxidase-labeled anti- 
IgG conjugate i s  not commercially available. 
3.2.4. Species Binding. 
Serum samples from various marine mammals were tested to determine 
how well Protein A and Protein G bind to IgG of  each species. Serum samples 
tested included horse, goat, cow, seal, sea lion, sea otter, dolphin, and polar bear. 
Goat serum sewed as a positive control for Protein G, and a negative control for 
Protein A (Harlow and Lane, 1988). Worse and cow samples bind with both 
Protein A (++) and G (-+++I (Harlow and Lane, 1988). Each serum sample was 
diluted in 0.05 M carbonate buffer, pH 9.6, starting at l:4 then a 5 fold dilution 
series after that to reach a final 1 :500 dilution. Each sample was tested in 
duplicate against Protein A and Protein G. The ELISA described in 3.2.2. was 
used to complete this test, 
3.2.5. Dilution Buffer. 
Tris buffered saline + EDTA (TBSE), PBST, Milk Blocker solution 
(PBST + 5% non-fat dried milk), and PBST + 10% FBS were each tested to 
determine the optimal dilution buffer for both serum and conjugate dilutions. 
Two plates were used for each buffer. Each selution was used to dilute both the 
s e m  and conjugate, and each solution was also used to dilute either the 
conjugate or the serum while using PBST to dilute the other. The procedure 
described in 3.2.2. was used in this test. 
3.2.6. Protein A Dilutions. 
To determine the optimal conjugate dilution, four dilutions of protein A in 
PBST were tested: 1:500, 1 :1,000, 1:2,000, 1:4,000. Each dilution was tested 
under the procedure described in section 3,2.2. 
3.2.7. Determination of Optimal Serum Dilution. 
To determine the optimal serum dilution to be used for testing of seal sera, 
serial dilutions of four known positive and four known negative samples were 
tested. Sera were diluted in PBST in a two-fold dilution series beginning with a 
1 :4 diIution and ending with a 1 :$,I92 dilution. The iELISA was performed as 
described in section 3.2.2. 
3.2.8. Substrate Incubation. 
The ELISA procedure described in section 3.2.2. was used with only a few 
modifications. Sample sera were diluted ?:32, and peroxidase-labeled Protein A 
was diluted f :1000, all diluted in PBST. Upon addition of substrate, one column 
of positive controls and one column of negative controls were stopped by adding 
25 111 of 2 M H7S04 during each elapsed minute until the 6" minute. The plate 
was immediately read for OD value after each minute. 
3.3. Evaluating the iELESA: 
Harder et al. (1997) suggest that testing paired serum samples far specific 
antibodies is probably the method of choice when screening a population (Dierauf 
and Gulland, 2001). SNT is the current gold standard, so it was important to use 
this test to evaluate our iELISA. 
3.3.1. Serum Neutralization of Archived Samples. 
Serum samples from seal and sea lion species from parts of Hawaii, 
California, and pacific islands (505 total) were tested by serum neutralization for 
presence of SeHV-I antibodies. In a 96-well flat bottom tissue culture plate, 25 
pF o f  serum-free DMEM and 25 pl of undiluted serum were added to the bottom 
two rows of each plate, each sample in duplicate Sera were mixed using a 
multichannel pipettes set at 25 yl, transferring 25 p1 of diluted serum from row G 
through row A to obtain a serial 2-fold dilution series of sera. Using DMEM 
without FBS, vims was diluted to contain approximately 100 TCIDsd25 pl, and 
25 yl added to each well except the cell control row (row H). This resulted in a 
final Zfold dilution series (A-G) of 1 :4 through 1 :256. The plates were incubated 
for 1 hour at 37'C with 5% CO?. During this incubation, CrFK cells were 
hypsinized and diluted to 10' cells/ml in DMEM, At the end of the 1 hour 
incubation, 1 5 0 ~ 1  of the cell suspension (1.5 X 10" cells) were added to all wells. 
The plates were read after 4 days of incubation at 37°C with 5% CO2. Negative 
serum samples were identified by the presence of cytopathic effect (CPE) due to 
their lack of virus neutralizing antibodies. Sera that showed CPE in both wells a? 
a 1:4 dilution were considered negative. Positive samples lacked CPE due ta 
presence of anti-Sew- l neutralizing antibodies. The titer was determined by 
taking the reciprocal of the dilution of the last pair of wells that contained no 
Table 3.1 Geographical distribution of  seal and sea lion serum samples 
CPE. Titers of 6 and 8 were considered suspect. Samples that showed titers 28 
were considered positive. Toxic samples could not be reported because the cells 
were unable to grow due to serum toxicity. 
3.4. Results. 
ELISA SNT 
Protein A bound to serum antibodies with nearly a ten fold greater 
efficiency than protein G. Protein A had an optical density (OD) of nearly 2.000, 
whereas Protein G had approximately 0.200 OD value. Each conjugate did show 
a statistically significant difference in detecting positive, negative, and blank 
(PBST only) samples. This is illustrated in figure 3.1. However, when 
comparing each protein to various species, Protein A showed a much higher 
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binding ability and consistency to the tested species than Protein G, as illustrated 
in figures 3.2a and 3.2b. Protein A at a dilution of 1 : 1000 was determined to be 
optimal and was used in all subsequent ELISA testing. 
When comparing dilution buffers, PBST allowed for the greatest binding 
of Protein A and serum samples, without significantly increasing the background. 
TBSE allowed binding, but yielded more background in the blank (PBST only) 
wells. Milk blocker, when used as a diluting solution prevented any Protein A 
binding, but did allow serum to bind when using PBST as a diluting buffer for 
Protein A. PBST + 10% FBS also allowed both Protein A and serum binding 
without having significant background reactions. 
The final optimal conjugate dilution was determined to be a 1: 1000 
dilution in PBST. This dilution provided a linear curve with the serum dilution. 
Results ate illustrated in figure 3.3. All other dilutions tested could be useful, but 
provided either an inconsistent curve, or high background reactions. 
Optimal substrate incubation period was determined to be 2-3 minutes. 
Incubation shorter than 2 minutes did not allow enough time for adequate 
reaction. Incubation longer than 3 ininutes created significant background in 
negative sera. Results are illustrated in figure 3.4. 
3.4.1. SNT Results. 
Of the 505 seal and sea lion s e m  samples, 298 tested positive (titers >8), 
5 1 tested suspect (titers of 6 and 8), 127 samples tested negative, and 29 samples 
were toxic to the cell culture. Trends in titers between geographical regions were 
negligible since there were too few samples from one population to detect trends, 
with the exception of Alaskan harbor seals. Titers ranged from 4 through 192. 
with most falling between 4 and 32 (data not shown). 
3.4.2. iELISA Results. 
Of the 505 seal and sea lion serum samples tested, 386 (76.4%) tested 
positive and 1 19 (23.6%) tested negative against S e w -  1 antigen. Most negative 
(< 0.600 OD) serum samples had minimal (OD's I 0.200). Few negative serum 
samples produced OD's of 0.201 to 0.399. Four samples tested between 0.400 
and 0.599. Samples showing >0.600 OD were considered positive. All positive 
samples were geater than 0.800 OD, most of which exceeded a 0.900 OD value. 
Interpreted results are described in table 3. I .  Only serum samples that had 
reportable results by the SNT and ELISA (425 total) are represented in detail. 
Serum samples that had toxic or suspect results were classified as non-reportable. 
Specific trends were difficult to define as described in section 3.4.1. However, 
the Alaskan harbor seal population showed a slightly higher prevalence of SeHV- 
I as determined by ELISA than by SNT (91%). This can be attributed to the 
possibility of false positives from the ELISA from low titer (<4$ reports ftom the 
SNT, or false negative labeling by the SNT. 
3.4.3. Comparison of iEhISA and SNT. 
Results of comparisons are described in table 3.2 below. When 505 serum 
samples were titeted by SNT, endpoint titers could not be determined for 29 
samples that were either toxic or contaminated, 11 of which tested positive on the 
ELISA. Additionally, there were 5 1 samples that tested as suspect by SNT (titers 
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Figure 3.1 Protein A vs. Protein G Binding Results 
Comparison of Protein A vs. Protein G detection of known positive (Pos) and negative (Neg) 
samples against S e w - 1 .  The blank column values were subtracted out of each vabe. In  
each Dilution, the positive sample produced an OD value that was at least 2 times greater 
than the negative sample. 
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These figures describe the comparison of Protein A and Protein G binding reactivity towards 
various mammal sera. Goat serum was used as a positive control for Protein G, and a negative 
control for Protein A. Each bar is an average oftwo different amrnal sera. Horse and cow 
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Figure 3.3 Protein A Dilution Series I 
This figure shows mean relative OD (of 2, SeHV-1 positive harbor seals) of each conjugate 
dilution vs. serum dilution. 
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Figure 3.4 Substrate Incubation Time Results 
This figure shows the relative OD value of each serum sarnpIe over time (in minutes) when 
comparing positive vs. negative samples. 
Table 3.2 Agreement between SNT and ELISA for detection of 
antibody in 425 sample sera (Martin et al., 1988) 
ELISA 
Positive Negative Total Apparent Prevalence 
S NT Positive 298 3 30 1 0.708 
Negative 13 1 7 1 124 0.292 
Total 31 1 114 425 
Apparent prevalence 0.732 0.268 
Observed proportional agreement (298 * E 1 1 )/425 = 0.962 
Chance prop. agreement (0.732 X 0.708) + (0.268 X .292) = 0.597 
Observed minus chance agreement (0.962 - 0.597) = 0.365 
Max. possible agreement beyond chance level (1 - 0.597) = 0.403 
Agreement quotient kappa) (0.365/0.403 ) = 0.906 
Relative specificity (1  111124) = 89.5% 
Relative sensitivity (298130 1 ) = 99.0% 
that were 24 but less than 81, but all 51 suspect serum samples tested positive on 
the ELISA. Of the remaining 425 samples a total of 298 serum samples were 
positive by SNT and ELISA (70.1 %), 3 (0.7%) were negative by ELISA but 
positive by SNT, 1 1 T (26.1 %) were negative by both ELlSA and SNT, and I3 
(3.1 %) were positive by ELlSA but negative by SNT 
3.5. Discussion. 
Seal Herpesvirus is common world wide with as much as a 77% 
prevalence in some areas (Zamke et al., 1997). However, the prevalence of 
SeHV-1 was greater in our study (90%) than described by Zamke et al. (1997) 
(77%). SeHV-1 prevalence in other seal and sea lion populations were dimcult to 
observe due to low numbers of samples. Currently, the SW is the most 
commonly used diagnostic test to detect SeHV-1 antibodies. The SNT is labor 
intensive, and requires 4 days of incubation before results can be obtained. It is 
desirable to have a test available that is quicker, less expensive to run, and easily 
amenable for many samples. 
We standardized the ELSA to the SNT because of two criteria: a) the 
SNT is currently the only diagnostic method of detecting serum antibodies, and b) 
neutralizing antibodies are presently considered the best predictor of host immune 
status. The ELISA results were very simiIar to the SNT results. yielding only 16 
conflicting samples (Table 3.1 ). The cutoff OD line of 0.600 was established by 
comparing SNT and ELlSA results and using 3 times a mean of negatives on an 
ELISA. Even with that high of a cutoff, there were 1 3 false positives via ELISA. 
Western Blot testing will be used in future studies to determine the cause of this 
phenomenon. For the 3 false negatives, it may be necessaq to decrease the 
dilution to 1 : 1 0 or 1 : 16 to increase sensitivity. 
Our indirect ELlSA proved to be a rapid, sensitive, relatively inexpensive 
and specific method of detecting ScHV-1 antibodies. This test also has the ability 
to test a variety of marine mammal sera using Protein A as a conjugate. In 
comparison to the SNT, the ELISA offers a h ~ g h  sensitivity (99.0%) and 
specificity (89.5%) while decreasing the run time from 4 days to less than 5 hours. 
Additionally, the ELISA i s  less dependent on the need for serum and tissue 
culture qualities. Cell cultures have the potential to lose sensitivity to virus 
infection over series of passages, and some serum can be toxic to cell cultures. 
In reference to the serum quality, one pn'mary concern involves sample 
Contaminants in the serum sample can degrade antibodies andlor 
the pH to a level that effects antibody binding. Though a n t i w  degradation 
cannot be eliminated by this test, altered pH can be nullified by the dilution of 
1:32 in PBST. 
One problem observed in this ELlSA is the low substrate incubation 
period. This may be solved by diluting serum samples more than the determined 
1 :32. Additional testing of conjugate dilution may also be necessary. Another 
possible solution would be to increase the negative cutoff level if more substrate 
incubation is required. 
Agreement between the SNT and ELlSA were calculated by estimating 
the agreement quotient (kappa), following established procedures (Martin et al., 
1988). Our relative specificity (89.5%) and specificity (99.0%) are dependant on 
the SNT values. These values may increase as Western blotting is completed. 
There is a possibility that these values may increase if false SNT labeling i s  
detemined to occur. Our kappa value of 0.906 indicates a high level of absolute 
agreement between the SNT and ELISA. As indicated earlier, this value may 
increase if Western blotting determines that the conflicting SNT results are 
flawed. 
All 29 serum samples that resulted in suspect diagnosis by the SNT tested 
positive by our ELISA. We speculate that the neutralizing titer was minimal, but 
non neutralizing titers (i.e. antibodies against e q m e s ,  core proteins, etc. ) were 
readily detectable by the ELlSA. 
In this study we obtained products from one company ( S i p a  Chemical 
Co.). Possible explanations for our Protein A vs. Protein G binding and affinity 
results may be: a) peroxidae label may diminish Protein G binding, or b) possible 
problems with ordered batch c) Protein G dces not bind to the tested marine 
mammal sera. Scenarios a and c are unlikely due to their binding described in 
figures 3.2a and 3.2b, but still remain a slight possibility. Whatever the case, 
Protein A yielded adequate results. 
Tests that were not performed in this study, but will be tested in the future 
include: a) testing dogs and cats that have a history o f  canine or feline herpesvirus 
positive will be tested against seal herpesvirus type 1 antigen to detect cross- 
reactivity to serum antibodies, b) use the western blot to distinguish between h-ue 
positive and tme negative in comparison to the EClSA and SNT. These tests are 
imporbant in final diagnosis. If canine and feline samples are cross-reactive, then 
SNT is required to distinguish whether the samples ate SeHV-1 positive andor 
feline or canine herpesvirus positive. If it is found that they are not cross-reactive, 
this developed ELISA could stand alone in the diagnosis of SeHV-1. Though 
these tests were beyond the scope of this study, Western blot testing, and testing 
of dog and cat samples will be important in providing final efficacy of this test. 
CHAPTER IV 
SUMMARY AND CONCLUSIONS 
Seal herpesvirus type 1 is prevalent in seal and sea lion populations world 
wide, including populations off the European coasts of The Netherlands (Borst et 
al, 1986) and Germany (Howat et al, 1989), Atlantic and Pacific coasts of the 
United Stales (Harder et al., 1 996; King et al., 1 998Kennedy-Stoskopf et al, 1986; 
Gulland et al, 1997), Alaska and Russia (Zarnke et al, 1997) and Antarctica 
(Stenvets et al, 1992). All these seal populations also carry antibodies against 
SeHV-2. Due to the wide range of this disease, it i s  important to have an accurate 
means of diagnosing Sew-1 . 
Currently, there is only one means of  serological diagnosis, serum 
neutralization. The SNT is  the current gold standard, but i t is labor intensive, 
requires 4 days before results can be determined, and i s  highly dependent on the 
quaIity of serum to be tested, Thetefore, i t i s  important to have a test that can 
minimize these shortcomings while maintaining a high level of sensitivity and 
specificity. The ELISA described in this study maintains a high specificity 
(89.5%) and a high sensitivity (99%) and only reqmires less than 5 hours to nm. 
This ELISA is easily amenable to testing a far larger number of samples than an 
SNT ~ o u l d  be. This ELISA is also usable on many "poor" semrn samples that 
cannot be tested by SNT. 
IT was unfortunate that we were unable to develop a competitive MAb. 
Further testing can still be performed to determine future values. It will he 
interesting to see if some MAb's may be neutralizing, which may have value in 
the SNT for control purposes. IFAs and other imrnunohistochemical tests may 
also utilize these M b s .  It will also be interesting to test these bv Western 
blotting to detect feline and canine herpesvirus proteins that cross-react with 
SeHV- 1, which would be consistent with Martina et a1 . (2002). Western blotting 
will be limited to MAbs that detect linear amino acid sequences and will not be 
able to detect conformational amino acid sequence-recognizing MAbs. 
Though a cELlSA would have allowed for testing of any species without 
changing any of the procedure, the Protein A based iELlSA a~lows testing for 
several marine mamma1 serum samples on the same plate (Fig. 3.2a). Because of  
this, the described iELISA maintains the advantages that a cELISA would have 
yielded while being less complicated than the cELISA and possibly being more 
reliable. 
This study yielded a diagnostic method that nearly matched the gold 
standard results and possibly surpassed the reliability by distinpishing suspect 
samples into positive or negative status. This new ELISA was also able to detect 
serum antibodies against SeHV-1 that were toxic and unreadable on the SNT. 
Further testing via western blot needs to be performed to evaluate the overall 
performance of both the SNT and ELISA. This will allow added confidence 
levels to either test. Ef it is found that the conflicting results favor the ELISA, 
then the ELISA could be considered superior to the SNT. Also, testing dog and 
cat samples with histories of canine and feline herpesvirus infections is important 
to evaluate additional uses for this test, and may suggest that this ELTSA can 
either stand alone, or require SNT for differential diagnosis of SeHV-I, feline, 
and canine herpesvimes. This testing wilI be limited to Protein A binding to cat 
and dog IgG antibodies. If it is found that this ELISA i s  cross-reactive towards 
canine and feline herpesviruses to a high de~-ree (OD >0.600), then it would 
require SNT testing to properly identify the correct pathogen. If there is minimal 
cross-reactivity, then this ELlSA could stand alone in detection of SeHV-I 
antibodies. 
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